Thomas Tingry, Emmanuel Massy, Muriel Piperno, Maxime Auroux, Marie Kostine, Denis Maillet, Mona Amini-Adle, Nicole Fabien, Charline Estublier, David Goncalves, Nicolas Girard, Cyrille B Confavreux
New anti-cancer therapeutics have been developed in the recent years and dramatically change prognosis and patient management. Either used alone or in combination, immune checkpoint inhibitors (ICI), such as anti-CTLA-4 and anti-PD1/PD-(L)1, act by removing T-cell inhibition to enhance their antitumor response. This change in therapeutic targets leads to a break in immune-tolerance and a unique toxicity profile resulting in immune complications. These side effects, called Immune-Related Adverse Events (IrAEs), can affect all organs, with a wide range of clinical and biological presentations and severity...
June 2021: Bulletin du Cancer